Adam E Snook (Adam Snook)

Scopus Author ID ResearcherID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 44

Top Venues

NPJ Parkinson's disease

Biomolecules

Toxins

Immunotherapy

Thomas Jefferson University

Thomas Jefferson University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Thomas Jefferson University Sep 07 2017

United States

Assistant Professor :: Pharmacology and Experimental Therapeutics

Education History

Thomas Jefferson University

United States

PHD :: Immunology and Microbial Pathogenesis

Publications

Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
Lara Cheslow, Adam E Snook, Scott A Waldman
Biomarkers for Managing Neurodegenerative Diseases. Biomolecules 14 (4) (2024)
Ruchi P Patel, Guido Ghilardi, Yunlin Zhang, Yi-Hao Chiang, Wei Xie, Puneeth Guruprasad, Ki Hyun Kim, Inkook Chun, Mathew G Angelos, Raymone Pajarillo, Seok Jae Hong, Yong Gu Lee, Olga Shestova, Carolyn Shaw, Ivan Cohen, Aasha Gupta, Trang Vu, Dean Qian, Steven Yang, Aditya Nimmagadda, Adam E Snook, Nicholas Siciliano, Antonia Rotolo, Arati A Inamdar, Jaryse Harris, Ositadimma Ugwuanyi, Michael Wang, Alberto Carturan, Luca Paruzzo, Linhui Chen, Hatcher J Ballard, Tatiana Blanchard, Chong Xu, Mohamed Abdel-Mohsen, Khatuna Gabunia, Maria Wysocka, Gerald P Linette, Beatriz Carreno, David M Barrett, David Trent Teachey, Avery D Posey, Daniel J Powell, Christopher Tor Sauter, Stefano A Pileri, Vinodh Pillai, John Scholler, Alain H Rook, Stephen J Schuster, Stefan Klaus Barta, Patrizia Porazzi, Marco Ruella
CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Science immunology 9 (97) (2024)
Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
Lara Cheslow, Adam E Snook, Scott A Waldman
Biomarkers for Managing Neurodegenerative Diseases. Biomolecules 14 (4) (2024)
Lara Cheslow, Adam E Snook, Scott A Waldman
Biomarkers for Managing Neurodegenerative Diseases. Biomolecules 14 (4) (2024)
Lara Cheslow, Adam E Snook, Scott A Waldman
Biomarkers for Managing Neurodegenerative Diseases. Biomolecules 14 (4) (2024)
Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
Nguyen T Van, Karen Zhang, Rachel M Wigmore, Anne I Kennedy, Carolina R Melo-Silva, Jialing Huang, Manju Ambelil, Jose H Villagomez, Gerald J O'Connor, Randy S Longman, Miao Cao, Adam E Snook, Michael Platten, Gerard Kasenty, Luis J Sigal, George C Prendergast, Sangwon V Kim
Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15. Nature communications 14 (1) (2023)
Scott Waldman, Lara Cheslow, Matthew Byrne, Jessica Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. Research square (2023)
John C Flickinger, Ross E Staudt, Jagmohan Singh, Robert D Carlson, Joshua R Barton, Trevor R Baybutt, Jeffrey A Rappaport, Alicja Zalewski, Amanda Pattison, Scott A Waldman, Adam E Snook
Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy. NPJ vaccines 7 (1) (2022)
Ross E Staudt, Robert D Carlson, Adam E Snook
Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy. Cancer biology & therapy 23 (1) (2022)
Claudia Capparelli, Timothy J Purwin, McKenna Q Glasheen, Signe Caksa, Manoela Tiago, Nicole A Wilski, Danielle Pomante, Sheera Rosenbaum, Mai Q Nguyen, Weijia Cai, Janusz Franco-Barraza, Richard Zheng, Gaurav Kumar, Inna Chervoneva, Ayako Shimada, Vito W Rebecca, Adam E Snook, Kim Hookim, Xiaowei Xu, Edna Cukierman, Meenhard Herylyn, Andrew E Aplin
Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nature communications 13 (1) (2022)
Madison M Crutcher, Adam E Snook, Scott A Waldman
Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients. Expert review of clinical pharmacology 15 (11) (2022)
Madison M Crutcher, Trevor R Baybutt, Jessica S Kopenhaver, Adam E Snook, Scott A Waldman
Emerging drug targets for colon cancer: A preclinical assessment. Expert opinion on therapeutic targets 26 (3) (2022)
Adi Caspi, Ariana A Entezari, Madison Crutcher, Adam E Snook, Scott A Waldman
Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer. Personalized medicine 19 (5) (2022)
Daniel S Lefler, Adam E Snook, Babar Bashir
Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1. Immunotherapy 14 (11) (2022)
Robert Hughes, Adam E Snook, Adam C Mueller
The poorly immunogenic tumor microenvironment of pancreatic cancer: the impact of radiation therapy, and strategies targeting resistance. Immunotherapy (2022)
Jessica Kopenhaver, Madison Crutcher, Scott A Waldman, Adam E Snook
The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission. Expert opinion on biological therapy 21 (10) (2021)
Jagmohan Singh, Wilbur B Bowne, Adam E Snook
Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment. Vaccines 9 (11) (2021)
Lara Cheslow, Adam E Snook, Scott A Waldman
Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers. Biomarkers in medicine 15 (8) (2021)
John C Flickinger, Jeffrey A Rappaport, Joshua R Barton, Trevor R Baybutt, Amanda M Pattison, Adam E Snook, Scott A Waldman
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. Biomarkers in medicine 15 (3) (2021)
Ariana A Entezari, Adam E Snook, Scott A Waldman
Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. Expert opinion on therapeutic targets 25 (5) (2021)
Alicja Zalewski, Adam E Snook, Scott A Waldman
Stem cells as therapeutic targets in colorectal cancer. Personalized medicine 18 (2) (2021)
John C Flickinger, Jagmohan Singh, Robert Carlson, Elinor Leong, Trevor R Baybutt, Joshua Barton, Ellen Caparosa, Amanda Pattison, Jeffrey A Rappaport, Jamin Roh, Tingting Zhan, Babar Bashir, Scott A Waldman, Adam E Snook
Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. Journal for immunotherapy of cancer 8 (2) (2021)
Joshua R Barton, Adam E Snook, Scott A Waldman
From leptin to lasers: the past and present of mouse models of obesity. Expert opinion on drug discovery 16 (7) (2021)
Babar Bashir, John C Flickinger, Adam E Snook
Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers. Immunotherapy 13 (7) (2021)
Robert D Carlson, John C Flickinger, Adam E Snook
Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy. Toxins 12 (4) (2020)
Erik S Blomain, Jeffrey A Rappaport, Amanda M Pattison, Babar Bashir, Ellen Caparosa, Jonathan Stem, Adam E Snook, Scott A Waldman
APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. Cancer biology & therapy 21 (5) (2020)
Adam E Snook
Companion vaccines for CAR T-cell therapy: applying basic immunology to enhance therapeutic efficacy. Future medicinal chemistry 12 (15) (2020)
Jessica Kopenhaver, Robert D Carlson, Adam E Snook
Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies. Toxins 12 (6) (2020)
Amanda M Pattison, Joshua R Barton, Ariana A Entezari, Alicja Zalewski, Jeff A Rappaport, Adam E Snook, Scott A Waldman
Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity. Cancer biology & therapy 21 (9) (2020)
Tiane Chen, Ruxian Lin, Leela Avula, Rafiquel Sarker, Jianbo Yang, Boyoung Cha, Chung Ming Tse, George McNamara, Ursula Seidler, Scott Waldman, Adam E Snook, Marcel J C Bijvelds, Hugo R de Jonge, Xuhang Li, Mark Donowitz
NHERF3 is necessary for Escherichia coli heat-stable enterotoxin-induced inhibition of NHE3: differences in signaling in mouse small intestine and Caco-2 cells. American journal of physiology. Cell physiology 317 (4) (2019)
Trevor R Baybutt, John C Flickinger, Ellen M Caparosa, Adam E Snook
Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors. Clinical pharmacology and therapeutics 105 (1) (2019)
Adam E Snook, Trevor R Baybutt, Bo Xiang, Tara S Abraham, John C Flickinger, Terry Hyslop, Tingting Zhan, Walter K Kraft, Takami Sato, Scott A Waldman
Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. Journal for immunotherapy of cancer 7 (1) (2019)
Tara S Abraham, John C Flickinger, Scott A Waldman, Adam E Snook
TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C. Journal of immunology (Baltimore, Md. : 1950) 202 (4) (2019)
John C Flickinger, Ulrich Rodeck, Adam E Snook
Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines 6 (3) (2018)
Abraham G Lin, Bo Xiang, Dante J Merlino, Trevor R Baybutt, Joya Sahu, Alexander Fridman, Adam E Snook, Vandana Miller
Non-thermal plasma induces immunogenic cell death in vivo in murine CT26 colorectal tumors. Oncoimmunology 7 (9) (2018)
Babar Bashir, Adam E Snook
Immunotherapy regimens for metastatic colorectal carcinomas. Human vaccines & immunotherapeutics 14 (2) (2017)
Trevor R Baybutt, Allison A Aka, Adam E Snook
The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report. Toxins 9 (9) (2017)
Bo Xiang, Trevor R Baybutt, Lisa Berman-Booty, Michael S Magee, Scott A Waldman, Vitali Y Alexeev, Adam E Snook
Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells. Journal of immunology (Baltimore, Md. : 1950) 198 (9) (2017)
Michael S Magee, Crystal L Kraft, Tara S Abraham, Trevor R Baybutt, Glen P Marszalowicz, Peng Li, Scott A Waldman, Adam E Snook
GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology 5 (10) (2016)

Adam E Snook.css-eqlu8i{font-size:small;padding-left:4px;} (Adam Snook)

Publication Activity (10 Years)

Top Topics

Top Venues

Adam E Snook (Adam Snook)